Pap Smear Refined

OncologyONCOLOGY Vol 11 No 8
Volume 11
Issue 8

The high proportion of false negatives associated with Pap smears spurred the development of more effective collection and diagnostic techniques for cervical cells. The Pap smear, a universal standard in the detection of cervical cancer, has recently

The high proportion of false negatives associated with Pap smears spurredthe development of more effective collection and diagnostic techniquesfor cervical cells. The Pap smear, a universal standard in the detectionof cervical cancer, has recently been refined by two new approaches thatgreatly reduce the incidence of false negatives.

At the annual meeting of the Society of Gynecologic Oncologists, studydata was presented that showed that cervical cancer and precancer detectioncan be enhanced by the use of neural network (artificial intelligence)computer technology. More than 16,000 smears, reprocessed by the computer-basedPAPNET test, found many pre-cancerous abnormalities that had been missedby conventional screening. These slides were originally reported as negativedespite presenting with an abnormality. PAPNET testing was shown to identify10 times more false-negative smears than would have been detected by manuallyrescreening an equal number of smears.

The study was conducted by Laurie J. Mango, MD, of Neuromedical Systems,Inc. developer of the PAPNET test, and Gary L. Goldberg, MD and Irwin R.Merkatz, MD, both of the Albert Einstein College of Medicine. "Negative"smears were reviewed and reclassified across four categories: ASCUS/AGUS(atypical), LGSIL (low-grade squamous intraepithelial lesion), HGSIL (highgrade), and carcinoma. Three academic laboratory sites provided the archivedsmears for review.

Mead Johnson and company recently agreed to copromote another refinementto the Pap smear. Cytyc corporation launched its ThinPrep Pap Test in January,1997. In clinical trials , the test has proven to be significantly moreeffective than the conventional smear for the detection of low-grade andmore severe lesions and to markedly improve specimen quality. Mead Johnsonsigned on to distribute and market the test to obstetricians and gynecologiststhroughout the United States. Currently, over 400 laboratories in the UnitedStates employ the ThinPrep system for use in the diagnosis of various cancers.The ThinPrep System consists of the ThinPrep 2000 Processor and relatedreagents, filters and other supplies.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content